US justice department says pay-for-delay pharma deals may be unlawful
This article was originally published in SRA
Executive Summary
The US Department of Justice has told an appeals court that payments made by branded pharmaceutical companies to delay competition from generic drug manufacturers are “presumptively unlawful”. Companies involved in such “pay-for-delay” deals, it said, must justify their action to avoid antitrust liability1.